India’s Covaxin led to tolerable safety outcomes and enhanced immune responses: Lancet

According to the Lancet, all adverse events were mild and moderate and were more frequent after the first dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/39QqBtu
via IFTTT